NASDAQ · XGNHealthcareMedical Labs

Exagen financials

$8.30−2.12%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
Revenue$66.6M$55.6M$52.5M$45.6M$48.3M$42.0M$40.4M
Gross profit$38.8M$33.1M$29.5M$21.3M$27.7M$25.4M$21.6M
Gross margin58.3%59.5%56.1%46.9%57.4%60.6%53.4%
Operating income-$14.1M-$13.6M-$22.8M-$46.1M-$24.1M-$15.2M-$9.3M
Net income-$20.0M-$15.1M-$23.7M-$47.4M-$26.9M-$16.7M-$30.3M
Net margin−30.0%−27.2%−45.1%−104.0%−55.6%−39.8%−75.0%
Diluted EPS$-0.93$-0.83$-1.34$-2.77$-1.68$-1.32$-8.46
EBITDA-$12.0M-$11.9M-$20.7M-$39.0M-$23.1M-$14.6M-$8.7M
Operating cash flow-$13.6M-$13.3M-$14.5M-$32.1M-$20.3M-$14.1M-$9.7M
Free cash flow-$14.3M-$13.8M-$15.3M-$36.5M-$22.7M-$14.5M-$10.1M
Diluted shares21.6M18.2M17.7M17.1M16.0M12.6M3.6M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$32.2M$22.0M$36.5M$62.4M$99.4M$57.4M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$26.0M$20.6M$19.5M$29.0M$27.5M$26.7M
Total assets$58.0M$44.7M$56.9M$86.2M$123.4M$78.4M
Total liabilities$40.6M$35.1M$34.3M$43.8M$38.5M$36.5M
Shareholders' equity$17.4M$9.5M$22.7M$42.5M$84.9M$41.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology